EBS (Emergent BioSolutions) Days Payable : 55.29 (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Days Payable?

Emergent BioSolutions's average Accounts Payable for the three months ended in Dec. 2024 was $72 Mil. Emergent BioSolutions's Cost of Goods Sold for the three months ended in Dec. 2024 was $118 Mil. Hence, Emergent BioSolutions's Days Payable for the three months ended in Dec. 2024 was 55.29.

The historical rank and industry rank for Emergent BioSolutions's Days Payable or its related term are showing as below:

EBS' s Days Payable Range Over the Past 10 Years
Min: 46.37 Med: 71.62 Max: 133.96
Current: 48.36

During the past 13 years, Emergent BioSolutions's highest Days Payable was 133.96. The lowest was 46.37. And the median was 71.62.

EBS's Days Payable is ranked worse than
75.19% of 943 companies
in the Drug Manufacturers industry
Industry Median: 85.92 vs EBS: 48.36

Emergent BioSolutions's Days Payable declined from Dec. 2023 (55.44) to Dec. 2024 (55.29). It may suggest that Emergent BioSolutions accelerated paying its suppliers.

Emergent BioSolutions Days Payable Historical Data

The historical data trend for Emergent BioSolutions's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Days Payable Chart

Emergent BioSolutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

78.47

64.65

61.19

55.81

46.37

Emergent BioSolutions Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															55.44	67.02	30.22	66.24	55.29

Competitive Comparison of Emergent BioSolutions's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Days Payable distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Days Payable falls into.

Save Embed

;

Save Embed

;

Emergent BioSolutions Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Emergent BioSolutions's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (112.2	+	60.9)	/	2 )	/	681.3	*	365
=	86.55					/	681.3	*	365
=	46.37

Emergent BioSolutions's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (82.1	+	60.9)	/	2 )	/	118	*	365 / 4
=	71.5					/	118	*	365 / 4
=	55.29

Emergent BioSolutions Days Payable Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

0IGA:UK ER4:Germany ER4:Germany

Address

300 Professional Drive, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Executives

Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Marvin L White	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853